Infectious Disease Control

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Strategic executive hire adds to Company's global leadership team and positions the Company for continued growth DURHAM, N.C.and BEIJING, July 13, 2022 /PRNewswire/ -- Brii Biosciences Limited  ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national...

2022-07-13 19:00 2555

U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine

* Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG, Md. ,July 11, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-gene...

2022-07-11 20:10 3318

iGene Laboratory launches Monkeypox PCR test for the South East Asian region.

SINGAPORE, July 8, 2022 /PRNewswire/ -- iGene Laboratory, the molecular diagnostics laboratory subsidiary of INEX Innovate Pte Ltd, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) Monkeypox test in response to the recent outbreak of the virus.

2022-07-08 12:25 3207

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

The Company is working closely with its commercial partners to supply the combination therapy to patients in need  Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout  and first regulatory approval by the China NMPA in less than 20 months, validating the Com...

2022-07-07 07:10 3716

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...

2022-07-06 08:10 3675

Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

* Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 inEurope GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious inf...

2022-07-05 23:37 3181

Brii Biosciences Exercises Option for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China

Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure for HBV ...

2022-07-04 07:10 3211

IMG Partners with eMed to Provide Telehealth Proctored COVID-19 Tests to Groups of International Travelers

INDIANAPOLIS, July 1, 2022 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, has announced a new partnership with eMed, the architect behind the first virtually guided, rapid at-home COVID-19 certified test technology ...

2022-07-01 21:00 8108

GSK Spreads Awareness on Vaccine-Preventable Diseases, Attempting to Bridge the Vaccination Gap in Malaysia

Building public trust and educating on the importance of getting vaccinated KUALA LUMPUR, Malaysia, July 1, 2022 /PRNewswire/ -- GSK is a science-led global healthcare company, delivering vaccines that help protect people at all stages of life. GSK's new purpose is to unite science, technology an...

2022-07-01 09:16 3068

Seegene develops PCR test to detect monkeypox virus

* Assay targets monkeypox virus and can deliver results in 90 minutes * Company swiftly rolls out product using its automated assay development system * "Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics" SEOUL, South Korea, June 28, 2022 /PRN...

2022-06-28 19:00 2432

Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an expected enrollment of 30 subjects HANGZHOU, China and SHAOXING, China, June 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been ...

2022-06-28 18:11 2269

JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5

TIANJIN, China, June 27, 2022 /PRNewswire/ -- As the SARS-COV-2 Omicron subvariants BA.4 and BA.5 make their way across the EU and the US, Joysbio is able to give people the power to administer a rapid test for themselves at home. The Joysbio Coronavirus Antigen Rapid Test Kit can effectively det...

2022-06-27 15:30 2753

Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines

TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-19 vaccine ("R520A"), from the Food and Drug Administration ofthe P...

2022-06-27 14:47 2957

Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17

* Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 inEurope * Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in adolescents GAITHERSBURG, Md., June 24, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechn...

2022-06-24 03:24 3525

GILEAD SCIENCES NEW DATA HIGHLIGHTS PEOPLE LIVING WITH HIV WHO ARE VIRALLY SUPPRESSED EXPERIENCE SIMILAR HEALTH-RELATED QUALITY OF LIFE AS GENERAL POPULATION

– Data in Taiwan Shows That Antiretroviral Therapies Have Helped Transform HIV Into a Chronic Condition and Bring Positive Change in the Outlook for People Living with HIV– SINGAPORE, June 16, 2022 /PRNewswire/ -- Gilead Sciences, Inc. today announced results from an online survey that assessed ...

2022-06-16 11:15 2453

WHO visit photos unveiled - BGI Genomics supports post-pandemic recovery in Hong Kong

SHENZHEN, China, June 15, 2022 /PRNewswire/ -- World Health Organization (WHO) has recently unveiled photos from its Feb-Mar 2021 visit to Hong Kong as COVID-19 affected the city, covering community testing facilities in key locations such as the Hong Kong International Airport and the Morse Park...

2022-06-15 09:24 2853

Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia

* In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). * The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in pati...

2022-06-13 21:20 3023

EpiVax Poxvirus Vaccine Candidate Predicted to be Effective Against Monkeypox

PROVIDENCE, R.I., June 11, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces that it has developed VennVax,a smallpox vaccine candidate that is predicted to be highly effective against monkeypox. The development of this vaccine was funded by the National Institutes of Health (SBIR grant #R4...

2022-06-11 03:15 6431

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Data are consistent with the results of the global Phase 3 ACTIV-2 trial, demonstrating a favorable safety and tolerability profile in people with both severe and non-severe SARS-CoV-2 infections inChina Clinical benefits were observed in efficacy indicators such as RNA conversion rate, resoluti...

2022-06-09 19:00 2960

FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

* Novavax COVID-19 vaccine receives positive vote from U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee * If Emergency Use Authorization is granted by the FDA, the Novavax COVID-19 vaccine would become the first protein-based COVID-19 vaccine availa...

2022-06-08 09:23 2771
1 ... 891011121314 ... 66

Week's Top Stories